ArticleTherapeutic advances in medical oncology2018
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Article in Therapeutic advances in medical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
180 citing papers in PubMed, 2 syntheses or guidelines pooled it, 269 citations in OpenAlex.
- Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis.International journal of molecular sciences · 2021Pooled it
- Pooled it
- Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.Journal for immunotherapy of cancer · 2022Trial
- Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nature communications · 2021Trial
- Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.Journal for immunotherapy of cancer · 2019Trial
- NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- PD-L1 and PD-L2 regulate in cell-autonomous and N-glycosylation-dependent manners the pro-tumorigenic characteristics and functions of human cancer-associated fibroblasts.Molecular medicine (Cambridge, Mass.) · 2026Article
- Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- p53 expression and NLR could recognize distinct subtypes of lung adenocarcinoma with high expression of PD-L1 (TPS ≥ 50%), defined with 22C3 antibody.Discover oncology · 2026Article
- Functional and mechanistic inactivation of immune hubs orchestrates tumor development and progression in lung adenocarcinoma.Discover oncology · 2026Article
- Female sex is associated with worse survival in laryngeal head and neck squamous cell carcinoma.The oncologist · 2026Article
- Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patients.ESMO open · 2026Article
- The AICL-KLRF1 axis supports CD4-CD8 T cell communication and cytokine competence in pre-exhausted CD8EMBO reports · 2026Article
- The insider's perspective: The intracellular complosome and immune cell dynamics in cancer.Clinical and translational medicine · 2026Review
- Translational 3DFrontiers in immunology · 2026Article
- The IFN-γ response cycle: decoupling tumor killing from evolutionary selection in cancer immunotherapy.Frontiers in immunology · 2026Review
- Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.Haematologica · 2026Article
- Beyond immune surveillance: IFN-γ and PD-L1 as shapers of tumor plasticity in Non-Small Cell Lung Cancer (NSCLC).Frontiers in immunology · 2026Review
- Impact of immune-related adverse events on treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors.Frontiers in immunology · 2026Article
120 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgrammed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated
methodsTotal RNA from 17 NSCLC and 21 melanoma patients was analyzed by quantitative reverse transcription PCR. STAT3 and Rantes, YAP1 and CXCL5, DNMT1, RIG1 and TET1, EOMES, IFNG, PD-L1 and CTLA4, IKBKE and NFATC1 mRNA were examined. PD-L1 protein expression in tumor and immune cells and stromal infiltration of CD8
resultsA total of 17 NSCLC patients received nivolumab and 21 melanoma patients received pembrolizumab. Progression-free survival with nivolumab was significantly longer in NSCLC patients with high
conclusionsIFN-γ is an important marker for prediction of response to immune checkpoint blockade. Further research is warranted in order to validate whether IFNG is more accurate than PD-L1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.